Elanco

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

Retrieved on: 
Monday, April 11, 2022
Company, Private Securities Litigation Reform Act, Form 10-K, Partnership, DNA, Elanco, Sale, Nano, Immunotherapy, Forward-looking statement, Patient, NYSE, Vaccine, Research, SEC, Risk, BioNTech, Cancer, Regeneron Pharmaceuticals, Hoffmann-La Roche, Technology, LNC, Organic acid, RNA transfection, Nasdaq, Geneve 9640, Solution, Consultant, BNTX, Annual report, History, Infection, Fine chemical, Genentech, Pfizer

This can be achieved with the right technology that enables targeted vaccine delivery, said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech.

Key Points: 
  • This can be achieved with the right technology that enables targeted vaccine delivery, said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech.
  • Matinas LNC platform demonstrates encouraging capabilities for intracellular delivery, including the opportunity for oral delivery.
  • Under the terms of the agreement, Matinas will receive an upfront access fee to work exclusively with BioNTech, as well as additional research funding from BioNTech.
  • Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology

Retrieved on: 
Monday, April 11, 2022
Risk, Business development, Ginkgo Bioworks, Soarin' Eagle, Form 10-K, Therapy, Partnership, Leadership, Synthetic biology, Global Investors Summit, Forward-looking statement, K-12, Environmental health, Interpersonal relationship, NYSE, Annual report, Probiotic, SEC, Veterinarian, Livestock, Program, Environment, Biotechnology, PETS, CEO, Health, U.S. Securities and Exchange Commission, Agriculture, COVID-19 testing, LLC, Technology, Intention, Farmer, Securities Exchange Act of 1934, Ecosystem, Securities Act of 1933, Exchange, COVID-19, Suicidal ideation, Intellectual property, Computer, ELAN, Animal, Viking Global Investors, Disease, North American Pet Health Insurance Association, Security (finance), Dietary supplement, Pharmaceutical industry, Antibiotics, Risk management, Ginkgo, Food, Elanco

GREENFIELD, Ind. and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Key Points: 
  • and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.
  • By leveraging foundational programs from Elanco, intellectual property from both Elanco and Ginkgo, and an experienced team, BiomEdit should be well positioned as a stand-alone company to develop and launch innovative products to address unmet needs in animal health.
  • "Elanco is excited to continue its participation in the microbiome by partnering with Ginkgo, Viking Global Investors and Anterra Capital to create the next-generation animal health innovation player," said Jeff Simmons, president and CEO of Elanco Animal Health.
  • "Together, we see Ginkgo and BiomEdit addressing significant opportunities in the animal health industry with new breakthroughs based on microbiome science.

Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes

Retrieved on: 
Tuesday, March 29, 2022
Agriculture, Natural Resources, Health, Veterinary, Pharmaceutical, Exercise, Sale, Risk, Forward-looking statement, Interpersonal relationship, NYSE, Compliance, Broker, CUSIP, Citigroup, Veterinarian, PETS, Health, U.S. Securities and Exchange Commission, Shelby County v. Holder, Prospectus, Settlement, Security (finance), Farmer, Securities Exchange Act of 1934, Person, Securities Act of 1933, Exchange, ELAN, Debt-to-GDP ratio, Animal, Disease, Health insurance, Cryptocurrency, Food, Note, Elanco

Elanco Animal Health Incorporated (NYSE: ELAN) (Elanco) today announced the commencement of a cash tender offer (the Offer) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) (Elanco) today announced the commencement of a cash tender offer (the Offer) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No.
  • Holders who validly tender their Notes after the Early Tender Time but on or before the Expiration Time will be eligible to receive the Tender Offer Consideration which is equal to the Total Consideration minus the Early Tender Payment.
  • Elanco will announce whether it intends to exercise the Early Settlement Election following the Early Tender Time.
  • Holders must make their own decisions as to whether to tender their Notes, and, if so, the principal amount of Notes to tender.

 Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

Retrieved on: 
Tuesday, March 29, 2022
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Risk, Elanco, Veni, vidi, vici, Pfizer–BioNTech COVID-19 vaccine, MedRxiv, Vaccine, Research, SEC, Publication, Disease, Twitter, COVID-19, UK Health Security Agency, Annual report, Marketing, Pediatrics, BioNTech, RNA transfection, U.S. Securities and Exchange Commission, Science, MMWR, BNT162, Immunotherapy, Clinical trial, Program, Dixons Carphone, Severe acute respiratory syndrome coronavirus 2, Awareness, Company, LinkedIn, Social Science Research Network, News, Hospital, Cancer, Regeneron Pharmaceuticals, Hoffmann-La Roche, Safety, Pierre Geneves, Facebook, Peer review, YouTube, Salvation Army Vision Network, Infection, Pharmaceutical industry, Online gambling, Delta, Omicron, Genentech, Pfizer, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

Key Points: 
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.
  • BNT162b2 (PfizerBiontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design.

BioNTech to Report Full Year and Fourth Quarter 2021 Financial Results and Operational Update on March 30, 2022

Retrieved on: 
Wednesday, March 16, 2022
Geneve 9640, Immunotherapy, Elanco, Hoffmann-La Roche, Investor relations, BioNTech, RNA transfection, Company, Cancer, Regeneron Pharmaceuticals, Webcast, Infection, Online shopping, Vaccine, Genentech, Pfizer

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.

Key Points: 
  • A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.
  • Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Covetrus Names Matthew Salois President of Veterinary Study Groups (VSG)

Retrieved on: 
Wednesday, March 16, 2022
Data Management, Health, Technology, Practice Management, Software, General Health, Veterinary, Central Florida, Solution, Technology, University, VSG, American Veterinary Medical Association, Health, Mona Lisa Saloy, Economics, VMG, Veterinarian, Health care, Applied economics, Animal, Securities Exchange Act of 1934, Veterinary medicine, Security (finance), NASDAQ, Leadership, AVMA, Elanco, U.S. Securities and Exchange Commission, Substance Abuse and Mental Health Services Administration, Oklahoma Homeland Security Act, Policy, Securities Act of 1933, Management, Food

Veterinary Study Groups, Inc. (VSG), a subsidiary of Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, has named Matt Salois, Ph.D. to the role of President of VSG.

Key Points: 
  • Veterinary Study Groups, Inc. (VSG), a subsidiary of Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, has named Matt Salois, Ph.D. to the role of President of VSG.
  • In this position, Salois will be responsible for enhancing the success of VSG, a membership organization for the owners of more than 1,800 veterinary practices.
  • Matts combination of economic knowledge and veterinary industry experience is unrivaled, and his leadership will be invaluable as we work with each Veterinary Management Group (VMG) member and Covetrus to shape the future of veterinary care.
  • Salois team of veterinarians, business leaders, event planners, and administrative professionals will work to meet the needs of each VMG member practice.

Elanco Expands Commitment to Creating Shared Value, Launches New Initiative Empowering Small-Scale Producers in Sub-Saharan Africa

Retrieved on: 
Wednesday, March 16, 2022
Veterinary, Agriculture, Natural Resources, Pets, Health, Food, Beverage, Consumer, Retail, Food security, Cattle, Degenerative disease, Solution, Farmer, Acaricide, Health, Global Alliance, Partnership, Income, Investment, ELAN, Veterinarian, Multimedia, Disease, Animal, MITES, Climate change, Bill, Livestock, Lists of countries and territories, PETS, Sustainable Development Goals, Government of the United Kingdom, Bill & Melinda Gates Foundation, United Nations Sustainable Development Group, Elanco, Government, Private sector, Poultry, ESG, Interpersonal relationship, NYSE, UK Government Decontamination Service, Efficiency, Tick, GALVmed, Agriculture, Renewable energy, Food, Social

View the full release here: https://www.businesswire.com/news/home/20220316005069/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220316005069/en/
    Raising livestock is important to secure people's livelihood in Sub-Saharan Africa.
  • Additionally, Elanco commits to bringing its comprehensive product portfolio for cattle and poultry to Nigeria, opening a new market for the company.
  • At Elanco, our relentless commitment to making a positive change in the world is core to our purpose.
  • Building on the success of Elancos first shared value initiative in East Africa, East Africa Growth Accelerator , the new initiative will provide local cattle farmers with innovative solutions that help address current acaricide resistance issues.

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults

Retrieved on: 
Tuesday, March 15, 2022
Twitter, U.S. Securities and Exchange Commission, SEC, Program, Pierre Geneves, EUA, Elanco, Immunotherapy, Hoffmann-La Roche, BNT162, Peer review, Facebook, Annual report, Vaccine, Private Securities Litigation Reform Act, Pfizer–BioNTech COVID-19 vaccine, FDA, Publication, Risk, COVID-19, News, BioNTech, Science, Safety, Pediatrics, RNA transfection, Awareness, Clinical trial, Company, Research, Cancer, Regeneron Pharmaceuticals, COVID-19 vaccine, Infection, LinkedIn, Marketing, YouTube, Pharmaceutical industry, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

Retrieved on: 
Tuesday, March 8, 2022
Private Securities Litigation Reform Act, Elanco, Patient, Immunotherapy, BNTX, Entrepreneurship, PD-1, Safety, Annual report, Drug, Regeneron Pharmaceuticals, B cell, Large-cell lung carcinoma, BioNTech, Uridine, Efficiency, Company, SEC, Treatment of lung cancer, Cancer, Senior, Geneve 9640, Prostate cancer, Infection, Fast track (FDA), Antigen, Review, Lung cancer, Immune system, Nasdaq, GLOBE, RNA transfection, Neoplasm, Hoffmann-La Roche, Pharmaceutical industry, Vaccine, Sanofi, Nature, Cemiplimab, Pfizer, Genentech, NSCLC

Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform.

Key Points: 
  • Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform.
  • We look forward to further building on our successful collaboration with Regeneron to accelerate the clinical development of BNT116 in our growing mRNA oncology pipeline.
  • The companies plan to develop the collaboration beginning with Phase 1/2 clinical trials in the first-line treatment setting in advanced NSCLC.
  • The agreement follows the companys existing collaboration evaluating the combination of BioNTechs FixVac candidate BNT111 with Libtayo in advanced melanoma.

Industry Expert Steve Dietze Joins Trace Genomics as VP of Strategic Operations

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, University of Nebraska at Kearney, Rockhurst University, Entrepreneurship, Health, Agtech, AG, Forbes, Elanco, Retirement, Wilbur-Ellis Co. v. Kuther, University, Genomics, Eli Lilly and Company, Soil, Economics, Dietze, DNA, Machine learning, Food, Technology, World Economic Forum, CEO, Management, Agriculture, Farmland Industries

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Trace Genomics has announced Steve Dietze as its new vice president of strategic operations.

Key Points: 
  • REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Trace Genomics has announced Steve Dietze as its new vice president of strategic operations.
  • Dietze's extensive experience in operations will further solidify Traces' excellence in commercial operations positioning them for advancement.
  • Following his retirement from Wilbur-Ellis, he worked as vice president of business development for EFC Systems.
  • "Trace Genomics' platform digitizes and decodes the living soil using genomics, advanced science, and machine learning.